Calliditas Therapeutics AB
WEBCONTACT US. Calliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
FDA grants Calliditas full nod for kidney disease drug Tarpeyo
WEBDec 20, 2023 · Pharma. Calliditas wins over FDA for full approval, broader label on kidney disease drug Tarpeyo. By Kevin Dunleavy Dec 20, 2023 5:24pm. Calliditas immunoglobulin kidney disease Tarpeyo. Two...
Calliditas Therapeutics announces full FDA approval of …
WEBDecember 20, 2023 22:15 CET Regulatory. Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy …
About Us – Calliditas Therapeutics AB
WEBCalliditas is a commercial stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.
Calliditas Therapeutics AB (publ) (CALT) - Yahoo Finance
WEB5.10. +4.72%. Find the latest Calliditas Therapeutics AB (publ) (CALT) stock quote, history, news and other vital information to help you with your stock trading and investing.
Breaking new ground with a late-phase rare-disease pipeline
WEBHaving been the first company to deliver positive phase 3 data in the rare disease immunoglobulin A nephropathy (IgAN), Calliditas is awaiting regulatory approval decisions in the US and European...
Calliditas Therapeutics announces full FDA approval of …
WEBDec 20, 2023 · Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function. PR Newswire. Wed, Dec 20...
Calliditas Receives FDA Fast Track Designation for setanaxib in PBC
WEBAug 9, 2021 · Calliditas’ lead product candidate, Nefecon, is a proprietary, novel oral formulation of budesonide, an established, highly potent local immunosuppressant, for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN, for which there is a high unmet medical need and there are no approved treatments.
Calliditas announces an additional seven year orphan drug …
WEBMar 6, 2024 · The exclusivity period reflects the new indication covering all adult patients with primary IgAN at risk of disease progression based on a confirmed reduction of kidney loss reflecting a clinical...
US FDA approves Sweden-based Calliditas' kidney disease drug
WEBDec 21, 2023 · Dec 20 (Reuters) - The U.S. Food and Drug Administration (FDA) granted full approval to Swedish drugmaker Calliditas Therapeutics' (CALTX.ST) drug to treat rare kidney disease IgA Nephropathy...
Skip to content